

**Outperformance in a seasonally weak quarter**

Information Technology ▶ Result Update ▶ January 25, 2024

**TARGET PRICE (Rs): 760**

**Birlasoft's operating performance outperformed our estimates in Q3. Revenue grew 1.9% QoQ (1.8% in cc), ahead of our estimates of 1.1% QoQ cc growth. In Q3, Birlasoft managed to negate the impact of furloughs through some short-term project execution and change requests. EBITDA margin expanded 20bps QoQ to 16%, despite the impact of incremental two months of wage hike, offset by operational efficiencies, improving utilization, and reducing sub-contracting costs along with higher contribution of short-term and change request projects. There is a conscious strategy to focus on short-term projects, which may increase some revenue volatility, in our view. Deal wins for 9MFY24 have increased 9% YoY, but net new deals have fallen ~3%. As per management, there has been no material improvement in the demand environment, as customers continue to remain cautious. We have increased our FY24-26E EPS estimates by 2-5%, factoring in Q3 performance beat. We maintain REDUCE, given rich valuations with a revised TP of Rs760 at 26x its Dec-25E EPS.**

**Birlasoft: Financial Snapshot (Consolidated)**

Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	41,304	47,948	52,972	60,981	69,715
EBITDA	6,401	5,205	8,398	9,834	11,590
Adj. PAT	4,637	3,316	6,027	7,020	8,424
Adj. EPS (Rs)	16.3	11.9	21.4	25.0	30.0
EBITDA margin (%)	15.5	10.9	15.9	16.1	16.6
EBITDA growth (%)	21.0	(18.7)	61.3	17.1	17.9
Adj. EPS growth (%)	43.0	(27.1)	81.0	16.5	20.0
RoE (%)	19.5	13.2	22.6	22.4	22.8
RoIC (%)	37.6	26.6	46.3	52.2	58.3
P/E (x)	50.4	69.2	38.4	32.9	27.5
EV/EBITDA (x)	34.6	42.0	25.7	21.5	17.8
P/B (x)	9.0	9.4	8.0	6.8	5.8
FCFF yield (%)	0.9	2.2	2.6	2.8	3.4

Source: Company, Emkay Research

**Results Summary**

Revenue grew 1.9% QoQ (1.8% in cc) to USD161.3mn, above our estimates of USD159.9mn. All service offerings reported sequential growth during the quarter – Data and Analytics (1.1% QoQ), Digital and Cloud (1.9%), ERP (0.6%), and Infrastructure (9.6%). Among verticals, Energy and Utilities (7.8% QoQ), Manufacturing (1.9%), and Lifesciences (1.5%) reported growth, while BFSI reported a decline of 0.5% QoQ. Both North America (1.8% QoQ) and ROW (2.6%) reported growth in the quarter. EBITDA margin expanded 20bps QoQ to 16%, higher than our estimate of 15.2%. TCV of deals fell to USD218mn (book to bill of 1.4x) from USD271mn in Q2 (9MFY24 – USD635mn, up 9% YoY). Net new deals declined to USD94mn in Q3 from USD167mn in Q2 (9MFY24 – USD341mn, down 3% YoY). Total headcount inched up by 0.3% QoQ to 12,356. **What we liked:** Strong operating performance and healthy cash conversion (141% OCF/EBITDA). **What we did not like:** Weaker deal wins (especially net new) and muted headcount addition (-1.4% YoY).

**Earnings Call KTAs**


i) The company has undertaken multiple sales and efficiency initiatives, of which one of them is Optimus. It is an internal tech transformation program, which focuses on the next wave of profitable growth, industrializing delivery, becoming a partner of choice in emerging technologies, enhancing the employee experience, and building a best-in-class talent pool. ii) Total TCV for 9MFY24 is up 9% YoY and management aims to wrap up Q4 with sequentially higher deal TCV signings, positioning the company well for FY25. iii) Revenue in Q3 was driven by deal ramp-ups, ability to pursue and execute short-term projects, and change requests, partially offsetting the impact of furloughs. iv) Energy and Utilities grew 7.9% QoQ due to the ramp-up of new deals. v) BFSI declined 0.7% QoQ and was impacted by higher furloughs. vi) The number of active clients stands at 272 in Q3 (vs. 299 in Q3FY23), reflecting continuous efforts of rationalizing tail accounts. Management highlighted that rationalization of tail accounts is largely over and may review it depending on the demand environment. vii) The company witnessed growth across infrastructure, which grew 9.6% QoQ, digital and cloud grew 2.1%, reflecting ramp-ups in a few new cloud teams, as well as some one-time revenue. The ERP service line continues its sequential growth trajectory in Q3 (up 0.5%), whereas data and analytics recorded 1.1% sequential growth. viii) Management highlighted that senior leadership hiring is largely done barring some strategic roles like Chief Strategy Officer.

Target Price – 12M	Dec-24
<b>Change in TP (%)</b>	<b>4.8</b>
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	(7.6)
CMP (24-Jan-24) (Rs)	822.7

Stock Data	Ticker
52-week High (Rs)	828
52-week Low (Rs)	250
Shares outstanding (mn)	275.7
Market-cap (Rs bn)	227
Market-cap (USD mn)	2,729
Net-debt, FY24E (Rs mn)	-15,331
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	1,681.8
ADTV-3M (USD mn)	20.2
Free float (%)	59.0
Nifty-50	21,454
INR/USD	83.1
<b>Shareholding, Dec-23</b>	
Promoters (%)	41.0
FPIs/MFs (%)	21.3/20.2

Price Performance				
(%)	1M	3M	12M	
Absolute	11.0	56.3	168.7	
Rel. to Nifty	10.5	40.5	126.9	

**1-Year share price trend (Rs)**



**Dipesh Mehta**

dipeshkumar.mehta@emkayglobal.com  
+91 22 6612 1253

**Ayush Bansal**

ayush.bansal@emkayglobal.com  
+91 22 6612 1344

**Pulkit Chawla**

pulkit.chawla@emkayglobal.com  
+91 22 6642 4258

**Exhibit 1: Quarterly snapshot**

(Rs mn)	Q3FY24	Q2FY24	QoQ (%)	Q3FY23	YoY (%)
Revenue (USD)	161.3	158.3	1.9	148.4	8.7
Net sales	13,430	13,099	2.5	12,219	9.9
Operating expenses	11,287	11,027		12,145	
EBITDA	2,143	2,071	3.4	74	NM
Margins (%)	16.0	15.8	10.0	0.6	NM
Depreciation	211	215		210	
EBIT	1,932	1,856	4.1	-136	NM
Margins (%)	14.4	14.2	20.0	-1.1	NM
Interest paid	59.5	56.9		55.6	
Forex Gains/(Losses)	66	-47		69	
Other income	216	203		54	
Pre-tax profit	2,154	1,955	10.2	-68	
Tax provided	544	504		95	
Profit after tax	1,611	1,451		-164	
Emkay net profit	1,611	1,451	11.0	-164	NM
EPS (Rs)	5.8	5.2	11.1	-0.6	NM

Source: Company, Emkay Research

**Exhibit 2: Actual vs estimates**


(Rs mn)	Actual	Estimate		Variation (%)		Comment
		Emkay	Consensus	Emkay	Consensus	
Sales (USD mn)	161	160	160	0.9%	0.8%	Revenue came ahead of our expectations.
Sales (Rs mn)	13,430	13,318	13,334	0.8%	0.7%	
EBIT	1,932	1,798	1,814	7.4%	6.5%	
EBIT margin	14.4%	13.5%	13.6%	90 bps	80 bps	EBITM came 90bps above expectations.
PAT	1,611	1,422	1,427	13.3%	12.9%	PAT beat estimates due to strong operating performance.

Source: Company, Bloomberg, Emkay Research

**Exhibit 3: Changes in estimates**

All figures in Rs mn except EPS and %	FY24E			FY25E			FY26E		
	Old	New		Old	New		Old	New	
Revenue (USD mn)	637	640	0.5%	720	726	0.9%	813	820	0.9%
YoY growth (%)	7.0	7.5		13.0	13.5		13.0	13.0	
Revenue	52,740	52,972	0.4%	60,445	60,981	0.9%	69,103	69,715	0.9%
EBIT	7,331	7,528	2.7%	8,671	8,873	2.3%	9,955	10,485	5.3%
EBIT margin (%)	13.9	14.2		14.3	14.6		14.4	15.0	
Net profit	5,790	6,027	4.1%	6,860	7,020	2.3%	8,007	8,424	5.2%
EPS (Rs)	20.7	21.4	3.7%	24.5	25.0	2.0%	28.6	30.0	4.8%

Source: Company, Emkay Research

**Exhibit 4: BSOFT one-year forward P/E**

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 04/26/2024 11:44 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY&lt;GO&gt;. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## Birlasoft: Consolidated Financials and Valuations

Profit and Loss					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
<b>Revenue</b>	<b>41,304</b>	<b>47,948</b>	<b>52,972</b>	<b>60,981</b>	<b>69,715</b>
Revenue growth (%)	16.2	16.1	10.5	15.1	14.3
<b>EBITDA</b>	<b>6,401</b>	<b>5,205</b>	<b>8,398</b>	<b>9,834</b>	<b>11,590</b>
EBITDA growth (%)	21.0	(18.7)	61.3	17.1	17.9
Depreciation & Amortization	765	823	870	961	1,106
<b>EBIT</b>	<b>5,636</b>	<b>4,382</b>	<b>7,528</b>	<b>8,873</b>	<b>10,485</b>
EBIT growth (%)	25.6	(22.3)	71.8	17.9	18.2
Other operating income	0	0	0	0	0
Other income	662	228	723	811	1,106
Financial expense	130	186	206	198	207
<b>PBT</b>	<b>6,168</b>	<b>4,424</b>	<b>8,045</b>	<b>9,486</b>	<b>11,384</b>
Extraordinary items	(1)	0	0	0	0
Taxes	1,531	1,108	2,019	2,466	2,960
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
<b>Reported PAT</b>	<b>4,636</b>	<b>3,316</b>	<b>6,027</b>	<b>7,020</b>	<b>8,424</b>
PAT growth (%)	44.5	(28.5)	81.8	16.5	20.0
<b>Adjusted PAT</b>	<b>4,637</b>	<b>3,316</b>	<b>6,027</b>	<b>7,020</b>	<b>8,424</b>
<b>Diluted EPS (Rs)</b>	<b>16.3</b>	<b>11.9</b>	<b>21.4</b>	<b>25.0</b>	<b>30.0</b>
Diluted EPS growth (%)	43.0	(27.1)	81.0	16.5	20.0
<b>DPS (Rs)</b>	<b>4.5</b>	<b>3.5</b>	<b>6.0</b>	<b>7.0</b>	<b>8.0</b>
<b>Dividend payout (%)</b>	<b>27.3</b>	<b>29.1</b>	<b>27.6</b>	<b>27.6</b>	<b>26.3</b>
EBITDA margin (%)	15.5	10.9	15.9	16.1	16.6
EBIT margin (%)	13.6	9.1	14.2	14.6	15.0
Effective tax rate (%)	24.8	25.1	25.1	26.0	26.0
<b>NOPLAT (pre-IndAS)</b>	<b>4,237</b>	<b>3,284</b>	<b>5,639</b>	<b>6,566</b>	<b>7,759</b>
Shares outstanding (mn)	281.0	275.6	276.7	276.7	276.7

Source: Company, Emkay Research

Cash Flows					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	6,168	4,424	8,045	9,486	11,384
Others (non-cash items)	987	3,300	870	961	1,106
Taxes paid	(1,784)	(1,315)	(2,019)	(2,466)	(2,960)
Change in NWC	(2,563)	(800)	(275)	(808)	(824)
<b>Operating cash flow</b>	<b>2,807</b>	<b>5,609</b>	<b>6,621</b>	<b>7,173</b>	<b>8,706</b>
Capital expenditure	(617)	(565)	(770)	(820)	(1,030)
Acquisition of business	(2,776)	2,844	0	0	0
Interest & dividend income	326	238	0	0	0
<b>Investing cash flow</b>	<b>(3,067)</b>	<b>2,517</b>	<b>(770)</b>	<b>(820)</b>	<b>(1,030)</b>
Equity raised/(repaid)	79	(4,615)	0	0	0
Debt raised/(repaid)	0	0	0	0	0
Payment of lease liabilities	(405)	(403)	0	0	0
Interest paid	(30)	(95)	0	0	0
Dividend paid (incl tax)	(1,111)	(1,250)	(1,686)	(1,968)	(2,249)
Others	0	0	0	0	0
<b>Financing cash flow</b>	<b>(1,467)</b>	<b>(6,362)</b>	<b>(1,686)</b>	<b>(1,968)</b>	<b>(2,249)</b>
Net chg in Cash	(1,755)	1,763	4,165	4,385	5,427
OCF	2,807	5,609	6,621	7,173	8,706
Adj. OCF (w/o NWC chg.)	5,370	6,409	6,896	7,980	9,530
FCFF	2,189	5,044	5,851	6,353	7,676
FCFE	2,386	5,096	5,646	6,155	7,469
OCF/EBITDA (%)	43.8	107.8	78.8	72.9	75.1
FCFE/PAT (%)	51.5	153.7	93.7	87.7	88.7
<b>FCFF/NOPLAT (%)</b>	<b>51.7</b>	<b>153.6</b>	<b>103.8</b>	<b>96.8</b>	<b>98.9</b>

Source: Company, Emkay Research

Balance Sheet					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	559	550	550	550	550
Reserves & Surplus	25,272	23,933	28,273	33,326	39,501
<b>Net worth</b>	<b>25,831</b>	<b>24,483</b>	<b>28,823</b>	<b>33,876</b>	<b>40,051</b>
Minority interests	0	0	0	0	0
Deferred tax liability (net)	(920)	(1,171)	(1,171)	(1,171)	(1,171)
<b>Total debt</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Total liabilities &amp; equity</b>	<b>24,910</b>	<b>23,312</b>	<b>27,652</b>	<b>32,705</b>	<b>38,880</b>
Net tangible fixed assets	1,468	1,423	1,496	1,505	1,518
Net intangible assets	94	138	132	122	108
Net ROU assets	1,116	902	735	596	521
Capital WIP	28	65	65	65	65
Goodwill	4,568	4,896	4,896	4,896	4,896
Investments [JV/Associates]	0	0	0	0	0
<b>Cash &amp; equivalents</b>	<b>12,230</b>	<b>11,166</b>	<b>15,331</b>	<b>19,716</b>	<b>25,144</b>
Current assets (ex-cash)	13,410	12,112	14,185	16,266	18,468
Current Liab. & Prov.	8,003	7,390	9,188	10,461	11,839
<b>NWC (ex-cash)</b>	<b>5,407</b>	<b>4,722</b>	<b>4,997</b>	<b>5,805</b>	<b>6,628</b>
<b>Total assets</b>	<b>24,910</b>	<b>23,312</b>	<b>27,652</b>	<b>32,705</b>	<b>38,880</b>
Net debt	(12,230)	(11,166)	(15,331)	(19,716)	(25,144)
Capital employed	24,910	23,312	27,652	32,705	38,880
<b>Invested capital</b>	<b>12,652</b>	<b>12,081</b>	<b>12,257</b>	<b>12,924</b>	<b>13,671</b>
BVPS (Rs)	91.0	87.7	102.5	120.5	142.5
Net Debt/Equity (x)	(0.5)	(0.5)	(0.5)	(0.6)	(0.6)
Net Debt/EBITDA (x)	(1.9)	(2.1)	(1.8)	(2.0)	(2.2)
Interest coverage (x)	0.0	0.0	0.0	0.0	0.0
<b>RoCE (%)</b>	<b>27.5</b>	<b>19.1</b>	<b>32.4</b>	<b>32.1</b>	<b>32.4</b>

Source: Company, Emkay Research

Valuations and Key Ratios					
Y/E March	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	50.4	69.2	38.4	32.9	27.5
P/CE(x)	43.2	55.5	33.5	29.0	24.3
P/B (x)	9.0	9.4	8.0	6.8	5.8
EV/Sales (x)	5.4	4.6	4.1	3.5	3.0
EV/EBITDA (x)	34.6	42.0	25.7	21.5	17.8
EV/EBIT(x)	38.8	49.2	28.2	23.4	19.3
EV/IC (x)	17.3	17.8	17.3	16.1	14.8
FCFF yield (%)	0.9	2.2	2.6	2.8	3.4
FCFE yield (%)	1.0	2.2	2.5	2.7	3.3
Dividend yield (%)	0.5	0.4	0.7	0.9	1.0
<b>DuPont-RoE split</b>					
Net profit margin (%)	11.2	6.9	11.4	11.5	12.1
Total asset turnover (x)	1.8	2.0	2.1	2.0	1.9
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0
<b>RoE (%)</b>	<b>19.5</b>	<b>13.2</b>	<b>22.6</b>	<b>22.4</b>	<b>22.8</b>
<b>DuPont-RoIC</b>					
NOPLAT margin (%)	10.3	6.8	10.6	10.8	11.1
IC turnover (x)	3.7	3.9	4.4	4.8	5.2
<b>RoIC (%)</b>	<b>37.6</b>	<b>26.6</b>	<b>46.3</b>	<b>52.2</b>	<b>58.3</b>
<b>Operating metrics</b>					
Core NWC days	47.8	35.9	34.4	34.7	34.7
<b>Total NWC days</b>	<b>47.8</b>	<b>35.9</b>	<b>34.4</b>	<b>34.7</b>	<b>34.7</b>
Fixed asset turnover	3.6	4.0	4.3	4.6	5.0
Opex-to-revenue (%)	84.5	89.1	84.1	83.9	83.4

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 04/26/2024 11:44 AM


Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY&lt;GO&gt;. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
31-Dec-23	721	725	Reduce	Dipeshkumar Mehta
30-Nov-23	630	540	Reduce	Dipeshkumar Mehta
01-Nov-23	572	540	Hold	Dipeshkumar Mehta
02-Oct-23	481	520	Hold	Dipeshkumar Mehta
27-Jul-23	400	390	Hold	Dipeshkumar Mehta
02-Jul-23	355	350	Hold	Dipeshkumar Mehta
09-May-23	305	340	Buy	Dipeshkumar Mehta
01-Apr-23	259	330	Buy	Dipeshkumar Mehta
03-Feb-23	265	325	Buy	Dipeshkumar Mehta
02-Jan-23	294	380	Buy	Dipeshkumar Mehta
22-Oct-22	276	370	Buy	Dipeshkumar Mehta
04-Oct-22	283	380	Buy	Dipeshkumar Mehta
04-Aug-22	345	400	Buy	Dipeshkumar Mehta
23-Jun-22	344	400	Buy	Dipeshkumar Mehta
01-Apr-22	455	530	Buy	Dipeshkumar Mehta
22-Feb-22	407	530	Buy	Dipeshkumar Mehta
28-Jan-22	435	550	Buy	Dipeshkumar Mehta
01-Jan-22	532	550	Buy	Dipeshkumar Mehta
30-Nov-21	464	550	Buy	Dipeshkumar Mehta
27-Oct-21	395	520	Buy	Dipeshkumar Mehta
02-Oct-21	386	500	Buy	Dipeshkumar Mehta
27-Aug-21	396	500	Buy	Dipeshkumar Mehta
29-Jul-21	394	460	Buy	Dipeshkumar Mehta
02-Jul-21	384	450	Buy	Dipeshkumar Mehta
22-May-21	258	330	Buy	Dipeshkumar Mehta
05-Apr-21	261	290	Hold	Dipeshkumar Mehta
18-Mar-21	233	290	Hold	Dipeshkumar Mehta

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of January 25, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of January 25, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the January 25, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	>15% upside
<b>ADD</b>	5-15% upside
<b>REDUCE</b>	5% upside to 15% downside
<b>SELL</b>	<15% downside

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India  
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.